ABI1 and cancer: This conclusion is supported by our co‐expression analysis between ABI1 and other members of the ABI1 survival (prediction) signature and the observed significant positive correlation between ABI1 expression, CNA, histologic grades, and basal‐like phenotype vs. ER(+) luminal cancer phenotype—the clinical markers of aggressiveness, metastasis, and drug resistance frequency.